Preclinical R&D

Internal R&D programs

Our research teams pursue R&D projects in different indications.

Cynbiome™

The 1^st preclinical excellence network on microbiome and infectious diseases grouping 12 partners.

More information on Cynbiome™.

National and world-class R&D programs

• Dendrim’s (ANR, 2011): An immuno-modulatory phosphorus-based dendrimer for the treatment of Multiple Sclerosis. This R&D program aimed at developing a model of EAE and test the efficacy of a dendrimer to prevent multiple sclerosis.
• Acilimab (FUI, 2011): Resistance treatment and optimization of cancer treatment by vectorisation of immune targeted active drug-substances. This project was dedicated to the development and characterization of mAb-targeted nanoparticules.
• Sting 2.0 (ANR, 2011): Immunostimulating molecules with a broad-spectrum antiviral activity : a proof of concept in non-human primate human respiratory syncytial virus model.
• Prim-OA (Eurostars, 2011): Development of non-human primate models for preclinical assessment of osteoarthritis treatments.
• Cyclops (ANR, 2015): Cyclosporine Apost-conditioning imaging in a primate stroke model.
• RHU Marvelous (ANR, French state investment plan, 2016): New MRI imaging to prevent cerebral and myocardial reperfusion injury.  Marvelous project website
• Metabiose (R&D Booster, 2019): The METABIOSE project aims to develop and characterize a translational NHP model of metapneumovirus infection (hMPV) and to validate drugs and a nebulization delivery device.

As Cynbiose is an R&D-performing SME, we are eligible for national and international R&D programs (ANR, FUI, Horizon Europe, … ) to carry out collaborative and innovative research projects.

We can also co-develop new models in partnership with our sponsor, share the risk and cost to increase success.